Dialysis-related amyloidosis is a serious complication of long-term hemodialysis. Its pathogenic mechanism involves accumulation of β2-microglobulin in the blood, which then forms amyloid fibrils and is deposited in tissues, leading to inflammation and activation of osteoclasts. Lixelle, a direct hemoperfusion column for adsorption of β2-microglobulin, has been available since 1996 to treat dialysis-related amyloidosis in Japan. However, previous studies showing the therapeutic efficacy of Lixelle were conducted in small numbers of patients with specific dialysis methods. Here, we report the results of a nationwide questionnaire survey on the therapeutic effects of Lixelle. Questionnaires to patients and their attending physicians on changes in symptoms of dialysis-related amyloidosis by Lixelle treatment were sent to 928 institutions that had used Lixelle, and fully completed questionnaires were returned from 345 patients at 138 institutions. The patients included 161 males and 184 females 62.9 ± 7.7 years age, who had undergone dialysis for 25.9 ± 6.2 years and Lixelle treatment for 3.5 ± 2.7 years. Based on self-evaluation by patients, worsening of symptoms was inhibited in 84.9-96.5% of patients. Of the patients, 91.3% felt that worsening of their overall symptoms had been inhibited, while attending physicians evaluated the treatment as effective or partially effective for 72.8% of patients. Our survey showed that Lixelle treatment improved symptoms or prevented the progression of dialysis-related amyloidosis in most patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1744-9987.2012.01130.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Self-Consistent Molecular Mechanism of β-Microglobulin Aggregation.
J Phys Chem B
December 2024
Physical and Materials Chemistry Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune, Maharashtra 411008, India.
Despite the consensus on the origin of dialysis-related amyloidosis (DRA) being β-microglobulin (βm) aggregation, the debate on the underlying mechanism persists because of the continuous emergence of βm variant- and pH-dependent contradictory results. By characterizing the native monomeric (initiation) and aggregated fibrillar (termination) states of βm via a combination of two enhanced sampling approaches, we here propose a mechanism that explains the heterogeneous behavior of wild-type (WT) and pathogenic (V27M and D76N) βm variants in physiological and disease-pertinent acidic pH environments. It appears that the higher retainment of monomeric native folds at neutral pH (native-like) distinguishes pathogenic βm mutants from the WT (moderate loss).
View Article and Find Full Text PDFA Case of Severe Post-Biopsy Bleeding and Perforation in Gastric Amyloidosis.
JGH Open
December 2024
Department of Gastroenterology and Hepatology Graduate School of Medicine, Kyoto University Kyoto Japan.
We herein describe a case of severe post-biopsy bleeding and perforation in gastric amyloidosis. A 70-year-old man who had been on dialysis underwent esophagogastroduodenoscopy and biopsy was performed. Post-biopsy bleeding occurred, and three times of coagulation hemostasis and once clip hemostasis were performed.
View Article and Find Full Text PDFA Rare Case of Multiple Myeloma Identified Following the Diagnosis of Amyloidosis of the Tongue.
Case Rep Dent
October 2024
Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata, Okayama 700-8525, Japan.
Amyloidosis is a disease in which amyloid protein is deposited in organs and tissues, resulting in functional impairment. Amyloidosis occurs in 12%-30% of patients with multiple myeloma, but in rare cases, amyloidosis may precede the diagnosis of multiple myeloma. Our patient was a 76-year-old Japanese male on dialysis.
View Article and Find Full Text PDFDegradation of pathogenic amyloids induced by matrix metalloproteinase-9.
Int J Biol Macromol
November 2024
Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology of the Russian Academy of Sciences, 4 Tikhoretsky ave., 194064 St. Petersburg, Russia. Electronic address:
Article Synopsis
- Over the past decade, research has focused on developing treatments for severe systemic and neurodegenerative diseases by targeting and degrading harmful amyloid deposits without significant side effects.
- This study investigates the impact of the immune enzyme MMP9 on various amyloids linked to Alzheimer's, Parkinson's, and other diseases, revealing that its effectiveness is influenced by the size of amyloid clusters.
- MMP9 degrades amyloids by disrupting their internal structures rather than just breaking hydrogen bonds, which helps avoid potential side effects from other anti-amyloid therapies while promoting the breakdown and safe handling of amyloid aggregates.
[New Development in Amyloidosis Research Based on Supersaturation: Biological Factors to Induce/Inhibit the Amyloid Fibril Formation].
Brain Nerve
April 2024
Graduate School of Engineering, Osaka University.
Article Synopsis
- Amyloid fibril formation occurs when certain proteins and peptides exceed their solubility, leading to a precipitation process similar to crystallization.
- Research using the HANABI inducer has shown that serum albumin inhibits amyloid fibril formation in dialysis-related amyloidosis.
- Understanding the factors that promote or prevent this fibril formation could help in developing early diagnostic tools and preventive strategies for amyloidosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!